Today: The Antares Pharma Inc. (ATRS) Lowered to Hold at Zacks Investment Research

The Antares Pharma Inc. (ATRS) Lowered to Hold at Zacks Investment Research

Zacks Investment Research cut shares of Antares Pharma Inc. (NASDAQ:ATRS) from a buy rating to a hold rating in a research note published on Tuesday.

According to Zacks, “Antares Pharma, Inc. develops, commercializes and markets novel delivery solutions, including needle-free and mini-needle injector systems, gel technologies and transdermal products, which improve both the efficiency of drug therapies and the quality of life for patients. The Company currently distributes its needle-free injector systems for the delivery of insulin and growth hormone in over 20 countries and an estradiol transdermal patch for hormone replacement therapy. “

Separately, Piper Jaffray Cos. restated an overweight rating and set a $2.00 target price (down from $3.00) on shares of Antares Pharma in a report on Saturday, August 13th.

Shares of Antares Pharma (NASDAQ:ATRS) opened at 1.76 on Tuesday. The firm has a 50-day moving average of $1.51 and a 200 day moving average of $1.12. The company’s market cap is $272.90 million. Antares Pharma has a 52 week low of $0.67 and a 52 week high of $1.85.

Antares Pharma (NASDAQ:ATRS) last posted its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.04) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.04). Antares Pharma had a negative net margin of 54.98% and a negative return on equity of 41.06%. The firm earned $12.20 million during the quarter, compared to the consensus estimate of $11 million. During the same period last year, the firm posted ($0.01) EPS. Equities analysts expect that Antares Pharma will post ($0.15) EPS for the current fiscal year.

Several large investors have recently modified their holdings of ATRS. Janus Capital Management LLC purchased a new stake in shares of Antares Pharma during the second quarter worth approximately $102,000. Oppenheimer & Co. Inc. increased its stake in shares of Antares Pharma by 19.1% in the second quarter. Oppenheimer & Co. Inc. now owns 112,300 shares of the specialty pharmaceutical company’s stock worth $118,000 after buying an additional 18,000 shares during the period. Jane Street Group LLC purchased a new stake in shares of Antares Pharma during the second quarter worth approximately $133,000. LMR Partners LLP purchased a new stake in shares of Antares Pharma during the second quarter worth approximately $297,000. Finally, Royce & Associates LP increased its stake in shares of Antares Pharma by 318.3% in the first quarter. Royce & Associates LP now owns 406,900 shares of the specialty pharmaceutical company’s stock worth $354,000 after buying an additional 309,616 shares during the period. Institutional investors and hedge funds own 36.34% of the company’s stock.

Antares Pharma Company Profile

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.

Related posts

Leave a Comment